New low-cost rotavirus vaccine could reduce disease burden in developing countries

Vaccine
Credit: National Cancer Institute

A new vaccine for rotavirus was found to be 66.7% effective in preventing severe gastroenteritis caused by the virus, according to a new study from researchers at Harvard T.H. Chan School of Public Health and Epicentre, Paris. Rotavirus is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age each year, or about 450,000 children, with a disproportionate effect in sub-Saharan Africa.

The study will be published in the March 23, 2017 issue of the New England Journal of Medicine.

Rotavirus is the leading cause of acute diarrhea, or severe gastroenteritis, in children. Unlike other causes of diarrhea, improvements in water, sanitation, and hygiene do not prevent transmission, therefore vaccination is essential to prevent death and complications from childhood diarrhea.

To make a difference in countries where the rotavirus burden is highest and access to health care is low, vaccines need to be affordable, as well as safe, effective, and heat-stable. Currently there are two rotavirus vaccines, but they are expensive and refrigeration must be maintained throughout the supply chain. In resource-poor countries such as Niger, electricity and refrigeration are often unreliable. The new vaccine is heat-stable, the first of its kind for rotavirus prevention.

"This trial brings a vaccine which is adapted to African settings to those who need it most," said first author Sheila Isanaka, assistant professor of nutrition at Harvard Chan School. "When the vaccine becomes widely available in Africa, it will help protect millions of the most vulnerable children."

For the trial, researchers conducted a randomized, placebo-controlled trial in Niger to evaluate the efficacy of BRV-PV, a low-cost, heat-stable vaccine manufactured by Serum Institute of India Pvt Ltd. The researchers recruited 3,508 healthy infants to receive three doses of the vaccine or placebo at 6, 10, and 14 weeks of age. All children included in the trial are monitored in local health centers and receive free for two years.

The vaccine has been licensed in India, but approval—known as prequalification— by the World Health Organization is needed before it can be purchased by the United Nations and government agencies. "After the successful clinical trial of this new , we hope that it can be made available as soon as possible to in Niger and across Africa," Isanaka said.


Explore further

Rotavirus vaccine given to newborns in Africa is effective

More information: "Efficacy of a Low-Cost, Heat-Stable Oral Rotavirus Vaccine in Niger," Sheila Isanaka, Ousmane Guindo, Celine Langendorf, Amadou Matar Seck, Brian D. Plikaytis, Nathan Sayinzoga-Makombe, Monica M. McNeal, Nicole Meyer, Eric Adehossi, Ali Djibo, Bruno Jochum, and Rebecca F. Grais, New England Journal of Medicine, March 23, 2017, DOI: 10.1056/NEJMoa1609462
Journal information: New England Journal of Medicine

Citation: New low-cost rotavirus vaccine could reduce disease burden in developing countries (2017, March 22) retrieved 23 May 2019 from https://medicalxpress.com/news/2017-03-low-cost-rotavirus-vaccine-disease-burden.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
20 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more